Taro Pharmaceutical Industries Ltd has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for granisetron hydrochloride tablets USP, 1 mg (base).

Taro's granisetron tablets is a prescription product used for the prevention of nausea and vomiting associated with chemotherapy and radiation treatment and is bioequivalent to Hoffman-La Roche, Inc's Kytril tablets, 1 mg (base). According to industry sources, granisetron tablets had US sales of approximately US$ 15 million in 2009.

Taro Pharma is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.